{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-057240","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.667179+00:00","generated_at":"2026-06-01T00:42:40.030277+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bluejay Diagnostics closes $8.75M public offering to repay debt and fund FDA work","bullets":["Gross proceeds $8.75M from sale of 5,368,098 units at $1.63/unit.","Units consist of 1 share (or pre-funded warrant), 2 Class C warrants, 1 Class D warrant.","Net proceeds to repay $2.3M debt and fund FDA approval (incl. clinical studies), R&D, working capital.","Class C warrants ($1.96 strike, 5-year term) require stockholder approval to become exercisable.","Underwriting discount 8.5%; Aegis Capital Corp. acted as sole underwriter."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-057240","json":"https://secwatch.observer/filing/0001213900-24-057240.json","markdown":"https://secwatch.observer/filing/0001213900-24-057240.md","text":"https://secwatch.observer/filing/0001213900-24-057240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024057240/0001213900-24-057240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024057240/ea0208666-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:42:40.030277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}